Presented by
Management Forum
Protein Engineering for Pharmaceutical Biotechnology Training Course
Advance your expertise in protein engineering with this comprehensive course. Learn cutting-edge techniques in therapeutic development, biotechnology applications, and regulatory compliance, ideal for professionals in pharmaceutical and industrial sectors.
10-11 September 2025
+ 21-22 January 2026 »
from £1299
- Format: Live online
- CPD: 12 hours for your records
- Certificate of completion
Course overview
Enhance your knowledge in protein engineering to understand how to advance therapeutic development and industrial applications.
Protein-based therapeutics have significantly advanced and created new paradigms in disease treatment. Half of the top ten selling drugs in 2023 are protein-based therapeutics.
Protein engineering, a field perfected by nature over billions of years, can now be replicated and customised in the laboratory within weeks. This course aims to equip professionals with the skills to develop more valuable and better-featured proteins, particularly enzymes, for a wide range of pharmaceutical applications. By understanding and applying the latest advancements in molecular biology, protein chemistry, enzymology, and structural chemistry, attendees will be able to create practical solutions that meet the needs of the pharmaceutical sector. The significance and timelessness of this training are underscored by the 2018 Nobel Prize for Chemistry, awarded for groundbreaking work in protein engineering, highlighting its growing importance and potential to revolutionise various industries.
This course is part of our Biopharma training courses series which aims to provide up-to-date knowledge on industry best practices and regulations surrounding biopharmaceuticals.
Benefits of attending
- Deepen your understanding of protein engineering concepts, enhancing your expertise in molecular biology, protein chemistry and enzymology
- Stay updated with the latest advancements in protein engineering, including CRISPR-Cas9 gene editing, phage display for protein-protein interactions, and mRNA therapeutics, keeping you at the forefront of the field
- Explore the development and application of protein-based therapeutics such as bispecific antibodies, antibody fragments, mRNA vaccines, antibody-drug conjugates, and antibody-directed enzyme pro-drug therapy
- Discover how protein engineering is used in biotechnology, including the development of genetically modified organisms (GMOs), biopharmaceuticals, directed evolution for enzyme production, and industrial enzymes
Who should attend?
This course is designed for professionals with a foundational understanding of biochemistry and molecular biology, seeking to deepen their knowledge and understanding in protein engineering, including:
- Biotechnology professionals
- Regulatory affairs professionals
- Pharmaceutical development specialists
- Quality assurance and control officers
- Clinical researchers
- Process development engineers
- Project managers
This course will cover:
Introduction to protein engineering
- Definition and Overview: What is Protein engineering?
- Proteins and their structure-function relationship
- Historical Background: Milestones in Protein engineering and biotechnology in pharmaceuticals
Techniques and tools in genetic engineering
- CRISPR-Cas9
- Mechanisms and applications in gene editing
- Recombinant DNA Technology
- How genes are spliced and introduced into host organisms
- Mutagenesis techniques, site-directed, random mutagenesis
- Gene cloning
- Cloning vectors, host organisms, and production of recombinant proteins
- Gene expression systems
- Bacterial, yeast, and mammalian cell expression systems for protein production
- RNA interference (RNAi)
- Mechanisms and therapeutic use for gene silencing in diseases
Pharmaceutical applications of protein engineering
- Biopharmaceuticals
- Production of therapeutic proteins (e.g., insulin, human growth hormone)
- Monoclonal antibodies (mAbs) for cancer, autoimmune diseases, etc.
- Gene therapy
- Correcting genetic disorders by inserting or modifying genes (e.g., treatments for hemophilia, cystic fibrosis)
- CRISPR-based gene editing for inherited diseases
- Vaccines
- Development of recombinant vaccines (e.g., hepatitis B vaccine)
- mRNA vaccines (e.g., COVID-19 vaccines)
Production of biopharmaceuticals
- Bioreactors and fermentation
- Use of genetically engineered microorganisms to produce drugs in large quantities
- Downstream processing
- Purification and scaling up of genetically engineered drugs
- Quality control
- Ensuring purity, potency, and safety of biopharmaceutical products
Ethical and regulatory considerations
- Ethics of genetic and protein engineering
- Ethical concerns surrounding genetic modifications in humans, animals, and microorganisms
- Regulatory frameworks
- FDA, EMA, and other global regulatory bodies for approving genetically engineered drugs
- Intellectual property
- Parenting genetically engineered products and processes
Advances in protein engineering for pharmaceuticals
- CRISPR-based therapies
- Engineering proteins for diagnostics
- Clinical trials and potential cures for genetic diseases
- Synthetic biology
- Designing new biological systems for drug production and personalised medicine
- Personalised medicine
- Tailoring treatments based on individual genetic profiles
- Biologics vs. small molecule drugs
- Differences and advantages of biologics developed through genetic engineering
Challenges in protein engineering for pharmaceuticals
- Safety Concerns
- Off-target effects in gene editing and immune responses to engineered proteins
- Cost and accessibility
- High production costs and making therapies accessible to a wider population
- Scalability
- Challenges in producing genetically engineered drugs on a large scale
Case studies and examples
- Insulin production
- How genetically engineered bacteria produce human insulin
- Gene therapy success stories
- Examples of successful gene therapies (e.g., Luxturna for inherited retinal disease)
- Monoclonal antibodies
- Their role in treating cancers and autoimmune diseases
Engineering modern drugs and targeted cancer therapy
- Checkpoint inhibitors
- CAR-T cancer therapy
- Antibody-drug conjugates (ADC)
- Antibody Directed ProDrug Therapy (ADEP)
Engineering of superantigens for targeted cancer therapy
Sayed Goda
University of Derby
Sayed K Goda, a biochemistry and drug discovery professor, has a robust academic background. He earned a BSc in Chemistry and an MSc in organic chemistry from Cairo University, Egypt. He then pursued a PhD in Biochemistry from the University of Southampton, UK. Recognising the pivotal role of technology management in his field, he obtained an MBA in technology management from the Open University, UK, in 2000. His diverse educational background equips him with a unique perspective and a broad range of skills, making him a valuable asset in the field of biochemistry and drug discovery.
After completing his PhD, Sayed embarked on a leadership journey at the Porton Down establishment in Salisbury, UK, where he served for fourteen years as a senior scientist and a team leader. During that time, he led commercial and medically sensitive research. He employed protein engineering to produce novel commercially and medically important proteins.
In 2002, Sayed's academic prowess and leadership skills led him to a professor position at Cairo University, Egypt. His tenure was marked by transformative contributions, notably the establishment of a new BSc Biotechnology program. He also supervised many successful MSc and PhD degrees.
In 2006, Dr. Goda accepted a professor position at Qatar University, Qatar, where he taught many major courses in biochemistry and biotechnology and successfully obtained many research grants.
In 2012, Sayed's expertise and reputation led him to a senior scientist and Professor position at the Antidoping laboratory in Qatar. He led research in various fields and established a protein engineering laboratory here. His exceptional ability to secure research funds, totalling over two million, for cancer-targeting drug discovery projects. His collaboration with Groningen University, Netherlands, resulted in the successful completion of four Ph. Ds and numerous publications, further solidifying his status as a prolific researcher.
Sayed has years of commercial and medical research experience in a conventional research institute in the UK.
He is also a regular reviewer for many high-impact journals, and he is currently a guest editor for Cancers.
NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:
- 30% off the 2nd delegate*
- 40% off the 3rd delegate*
- 50% off the 4th delegate*
Please contact us for pricing if you are interested in booking 5 or more delegates
10-11 September 2025
Live online
09:30-17:00 UK (London) (UTC+01)
10:30-18:00 Paris (UTC+02)
04:30-12:00 New York (UTC-04)
Course code 15503
- GBP 1,299 1,499
- EUR 1,819 2,099
- USD 2,087 2,399
Until 06 Aug
- 2 days live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
21-22 January 2026
Live online
09:30-17:00 UK (London) (UTC+00)
10:30-18:00 Paris (UTC+01)
04:30-12:00 New York (UTC-05)
Course code 15504
- GBP 1,299 1,499
- EUR 1,819 2,099
- USD 2,087 2,399
Until 17 Dec
- 2 days live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.
Germany
- Boehringer Ingelheim Vetmedica GmbH
Run Protein Engineering for Pharmaceutical Biotechnology Live online for your team
2 days
Typical duration
Pricing from:
- GBP 1,000
- Per attendee, based on 10 attendees
- Course tailored to your requirements
- At your choice of location, or online
We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.
Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:
